NasdaqCM:OTLKBiotechs
Outlook Therapeutics (OTLK) Stock Looks Fully Valued While Book Value Stays Unclear
Outlook Therapeutics stock has had a very difficult five years, with the share price down about 98.3%, and the latest valuation checks currently do not flag the stock as a clear bargain despite this steep decline.
Over the past five years, Outlook Therapeutics has declined around 98.3%, which means long term shareholders have seen most of their equity value eroded.
The recent approval and planned U.S. launch of LYTENAVA, supported by a US$55 million equity offering, can help fund growth but...